Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2003
06/12/2003WO2003048123A1 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
06/12/2003WO2003048116A2 Esters and amides as ppar-alpha agonists ____________
06/12/2003WO2003048106A2 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof
06/12/2003WO2003048101A1 Induction of apoptosis in cancer cells
06/12/2003WO2003048096A1 Substituted aryl-cycloalkanes, and use thereof as anticancer agents
06/12/2003WO2003047697A2 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
06/12/2003WO2003047634A2 Nucleic acids and methods for treating ebv-positive cancers
06/12/2003WO2003047633A2 Treatment of angiogenesis disorders using targeted nanoparticles
06/12/2003WO2003047621A1 CELL PROLIFERATION INHIBITOR CONTAINING ANTI-PepT ANTIBODY
06/12/2003WO2003047618A2 Immunotherapeutic methods and systems
06/12/2003WO2003047613A1 Use of c-jun or c-jun activating agents such as uv or c-jun n-terminal kinases (junks) for treating cancer
06/12/2003WO2003047611A2 Ptp10d, tec and edtp involved in triglycerid-metabolism
06/12/2003WO2003047608A1 A novel herbal chemical composition for the treatment of cancer
06/12/2003WO2003047606A2 Minor histocompatibility antigen ha-1: target antigen for immunotherapy of tumors
06/12/2003WO2003047595A1 Pharmaceutical compositions comprising active vitamin d compounds
06/12/2003WO2003047588A1 Kit for reducing aching caused by pde-v inhibitors
06/12/2003WO2003047587A1 Platinum derivative pharmaceutical formulations
06/12/2003WO2003047586A1 Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
06/12/2003WO2003047585A1 Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
06/12/2003WO2003047583A1 Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
06/12/2003WO2003047582A1 Quinoline derivatives as antitumour agents
06/12/2003WO2003047579A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
06/12/2003WO2003047571A2 Use of a kmo inhibitor for producing a pharmaceutical composition
06/12/2003WO2003047524A2 Methods and compositions for modulating the immune system and uses thereof
06/12/2003WO2003047523A2 Raf-mek-erk pathway inhibitors to treat cancer
06/12/2003WO2003047508A2 Paclitaxel solvates
06/12/2003WO2003047506A2 Peptide agonists of prostate-specific antigen, and uses therefor
06/12/2003WO2003047417A2 Ep4 receptor agonist, compositions and methods thereof
06/12/2003WO2003033523A3 Cytotoxic compounds
06/12/2003WO2003027282A9 Adamts-15, -16, -17, -18 and -19
06/12/2003WO2003024183A3 Wortmannin analogs and methods of using same
06/12/2003WO2003005962A3 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate
06/12/2003WO2002103031A3 Methods for detecting and treating the early onset of aging-related conditions
06/12/2003WO2002078703A8 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
06/12/2003WO2002068627A3 Vector constucts
06/12/2003WO2002064094A3 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
06/12/2003WO2002055692A3 Method for inhibiting the expression of a target gene and medicament for treating a tumor disease
06/12/2003WO2002018544A3 Method and reagents for treatment of skin disorders by modulating the notch pathway
06/12/2003WO2002000192A8 Embolization using carbon coated particles
06/12/2003WO2001088126A8 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
06/12/2003WO2001073133A9 Compositions and methods for identifying and targeting cancer cells
06/12/2003WO2001071007A3 GENETIC POLYMORPHISM OF MxA PROTEIN AND USE THEREOF
06/12/2003US20030109813 Energy-activated targeted cancer therapy
06/12/2003US20030109690 Colon and colon cancer associated polynucleotides and polypeptides
06/12/2003US20030109678 Methods and means for regulation of gene expression
06/12/2003US20030109674 Antiinflammatory agents; medical diagnosis; genetic engineered polypeptide
06/12/2003US20030109671 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/12/2003US20030109578 Treating acute and chronical inflammatory processes in a patent in need thereof which comprises administering to such patent an amount effective therefor of a compound or salt thereof according to claim 1.
06/12/2003US20030109572 Wortmannin analogs and methods of using same
06/12/2003US20030109570 Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases
06/12/2003US20030109567 Antitumor agent which comprises said compound or a physiologically acceptable salt thereof as an active ingredient.
06/12/2003US20030109556 Melanocortin receptor ligands
06/12/2003US20030109550 Substituted indazole compounds for the treatment of inflammation
06/12/2003US20030109545 Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors.
06/12/2003US20030109538 Pyrmidine derivatives as selective inhibitors of cox-2
06/12/2003US20030109535 GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:prodrugs, stereoisomers and drugs
06/12/2003US20030109527 Novel hydroxy diphenylurea sulfonamides, compositions and intermediates thereof. The hydroxy
06/12/2003US20030109518 Substituted 1,4-benzodiazepines and uses thereof
06/12/2003US20030109515 Pharmaceutical formulation of a platinum derivative
06/12/2003US20030109514 Platinum derivative pharmaceutical formulations
06/12/2003US20030109502 Novel compounds for modulating cell proliferation
06/12/2003US20030109500 Compositions and methods for use in targeting vascular destruction
06/12/2003US20030109497 Novel imidazolidine derivatives, their preparation and their use
06/12/2003US20030109491 Use of heparinoid derivatives for the treatment and diagnosis of disorders which can be treated with heparinoids
06/12/2003US20030109490 Composite stimulating iNOS enzyme which induce immuno-reactant nitric oxide synthesis and process for preparing the same
06/12/2003US20030109487 Deoxy-2'-(fluoromethylene)cytidine; and (b) administering to the patient an effective amount of a platinate; wherein the amounts of (E)-2'-deoxy-2'- (fluoromethylene)cytidine and platinate are selected to provide cellular proliferation
06/12/2003US20030109481 Tumour-cell specific gene expression and its use in cancer therapy
06/12/2003US20030109474 Gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor, of the signal transduction pathway is modified resulting in a modified AP-1 activity and
06/12/2003US20030109463 Novel macrolides
06/12/2003US20030109460 A pharmaceutical preparation which ensures stability and solubility of a hexacyclic camptothecin derivative prepared by adding a ring having a water-soluble group to camptothecin, wherein a pH-adjusting substance and, a sugar or sugar alcohol
06/12/2003US20030109454 Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof
06/12/2003US20030109452 Containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological applications.
06/12/2003US20030109449 Gastrointestinal tissue are described. Its formulation as a pharmaceutical, and its therapeutic and related uses in treating bowel tissue, are described. Also described are methods of identifying antagonist of glucogen-like
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109434 One or more kidney tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expression such
06/12/2003US20030109429 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
06/12/2003US20030109423 Cyclin- dependent kinases (Cdks) are important for driving cells through different phases of the cell cycle and their sequential activation and deactivation are tightly regulated activation of the mitotic Cdk, Cdc2, requires multiple events;
06/12/2003US20030109026 Genetically modified tumor-targeted bacteria with reduced virulence
06/12/2003US20030109022 Asp2
06/12/2003US20030109016 Tumor suppresison gene; anticancer agents
06/12/2003US20030108966 Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
06/12/2003US20030108965 Using polypeptide, detection of antibody; cancer of ovaries
06/12/2003US20030108961 Methods and compositions for diagnosing breast cancer
06/12/2003US20030108953 Truncated egf receptor
06/12/2003US20030108950 Measuring concentration in body fluid of tumor antibodies
06/12/2003US20030108937 Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
06/12/2003US20030108928 MID 241 receptor, a novel G-protein coupled receptor
06/12/2003US20030108623 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils as synergists for conventional treatments
06/12/2003US20030108622 Prophylactic or therapeutic treatment of soft tissue cancer, e.g. breast cancer; improving the effective treatment and reducing the adverse side effects of current anticancer therapy; antiproliferative, -carcinogenic agents
06/12/2003US20030108603 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar
06/12/2003US20030108597 Application of lipid vehicles and use for drug delivery
06/12/2003US20030108593 Reduction inhibitory agent for active oxygen eliminating activity
06/12/2003US20030108574 Carbohydrate-based whole cell cancer vaccines
06/12/2003US20030108573 Phenol, water solvent extraction using a protease
06/12/2003US20030108565 Sustained releas of protein using polymer and hydrophobic ion binding; inducing immunology response; autoimmune disease, anticancer agent
06/12/2003US20030108554 GIPs, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein
06/12/2003US20030108550 Anti-procalcitonin antibodies and the preparation and use thereof
06/12/2003US20030108545 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
06/12/2003US20030108544 Compositions and methods for the diagnosis and treatment of tumor
06/12/2003US20030108540 Inducing apoptosis in tissues; binding antibodies
1 ... 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 ... 2211